1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue

Amgen and Illumina Enter Agreement to Develop Oncology Companion Diagnostic Test

The Californian sequencing instrumentation leader, Illumina, entered into a partnership with Amgen to develop and commercialize a multigene next generation sequencing (NGS) based companion diagnostic test for the targeted drug Vectibix in metastatic colorectal cancer. This partnership marks Illumina’s entry into the NGS personalized medicine segment.

The Analyst’s Perspective by Divyaa Ravishankar, Senior Industry Analyst, Life Science North America

Various life science tools manufacturers have entered the companion diagnostic market segment in the last two years. The Amgen-Illumina partnership will be developing one of the first NGS-based companion diagnostic assays. The partnership leverages Illumina’s market leadership in NGS research platforms. The partnership also delivers a geographic advantage in the U.S. and Europe, which leads to an easier roadmap to address regulatory challenges. Illumina’s MiSeq sequencer has lowered the cost of sequencing relative to the competition, making it a suitable platform to develop the multi-gene test. Amgen partnered with Illumina for its strong track record in the commercialization of novel personalized medicine products. Examples include a partnership with DxS in 2008 for the KRAS companion diagnostic test and a partnership with Dako in 2012 for another companion diagnostic test associated with a rare cancer treatment.
NGS enables patient tumor genetic profiling and the NGS market segment is rapidly moving toward clinical diagnostics for its advantages to detect a large number of mutations simultaneously and affordably. Resulting from this work, physicians can choose the best possible treatment option personalized to the patient. In the next few years, Illumina will reap benefits from this novel diagnostic test, which will position the company in the high growth companion diagnostic segment.

Nestlé Launches New Dermatology Subsidiary Through Complete Acquisition of Galderma

Nestlé has made another strategic move in their transition toward a more healthcare focused company, with the full acquisition of dermatology specialty company, Galderma. Nestlé will fund this transaction with the sale of 48.5 million shares of Loréal in which Nestlé gains a 50% stake in Galderma from Loréal, resulting in 100% ownership of Galderma. Galderma will be the foundation of a new subsidiary, Nestlé Skin Health S.A. The transaction is pending regulatory approval.

Table Of Contents

Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue
Amgen and Illumina Enter Agreement to Develop Oncology Companion Diagnostic Test
Nestle Launches New Dermatology Subsidiary through Complete Acquisition of Galderma
Myriad Genetics Acquires Crescendo Bioscience for $270 Million
Fluidigm Corporation to Acquire DVS Sciences

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
The Chinese Market for DNA Sequencing

The Chinese Market for DNA Sequencing

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about recent advances and trends in the Chinese sequencing industry and market. - Analyze the Chinese sequencing market by workflow, including sample preparation products, ...

Agrigenomics Market by Application, Sequencer Type, Objective, and Region - Global Forecast to 2021

Agrigenomics Market by Application, Sequencer Type, Objective, and Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

“The agrigenomics market is projected to grow at a CAGR of 7.8%, in terms of value” The agrigenomics market is projected to reach USD 13.56 billion by 2021. Rising funds toward agrigenomics research ...

US Next-generation Sequencing Services Market

US Next-generation Sequencing Services Market

  • $ 4950
  • Industry report
  • September 2016
  • by Frost & Sullivan

$1,000 Genome Pricing and Throughput to Drive More and Larger Sequencing Projects The next-generation sequencing (NGS) services market includes all sequencing services conducted with next-generation o ...


Download Unlimited Documents from Trusted Public Sources

Genetic Industry in Denmark and Brazil

  • November 2016
    9 pages
  • Genetic  

  • Denmark  

    Brazil  

View report >

Global Nanomedicine Industry - Forecast

  • November 2016
    23 pages
  • Nanomedicine  

    Personal Genomi...  

    Gene Therapy  

  • United States  

    World  

    Japan  

View report >

Genome Sequencing Industry in the UK

  • November 2016
    29 pages
  • Genome Sequenci...  

    Infectious Dise...  

  • United Kingdom  

    United States  

View report >

Related Market Segments :

Genome Sequencing

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.